Literature DB >> 15717628

Influence of ischemia on heart-rate variability in chronic hemodialysis patients.

Isaline Coquet1, Christiane Mousson, Gerard Rifle, Gabriel Laurent, Daniel Moreau, Yves Cottin, Marianne Zeller, Claude Touzery, Jean Eric Wolf.   

Abstract

BACKGROUND: Sudden cardiac death occurring in patients with end-stage renal disease (ESRD) may be related to poor autonomic function with a significant decreased heart-rate variability (HRV). In addition, coronary artery disease has a high prevalence in this population and accounts for 50% of deaths. In the present study, relationships between HRV and myocardial ischemic abnormalities revealed by myocardial scintigraphy (MS) were evaluated in 32 chronic hemodialysis patients.
METHODS: We prospectively studied 32 chronic hemodialysis patients. Each underwent MS and 24 h electrocardiography at baseline for analysis of time and frequency domain the day of dialysis. Three periods were analyzed: during dialysis session, the morning after (nondialytic period), and in a 24 h period. Patients were included in group 1 (seven women, 11 men; mean age: 62+/-19 years) when MS revealed no ischemia, whereas patients were included in group 2 (seven women, seven men; mean age: 63.1+/-20 years) when MS revealed ischemic lesions.
RESULTS: A student+/-test revealed that during the nondialytic period, two important markers of HRV, percentage of delta RR>50 ms (pNN50) (4.5+/-4.04 in group 1 versus 1.7+/-1.4 in group 2), and root mean square of delta RR (rMSSD) (27.7+/-13.4 versus 19.7+/-6.8) were significantly reduced in group 2 compared with values in group 1. No significant difference appears between the two groups for standard deviation of normal to normal intervals (SDNN), mean heart rate, and spectral analysis.
CONCLUSION: Patients with ESRD and myocardial ischemia revealed by MS have reduced parasympathetic activity during the nondialytic period. Correlations between parameters of HRV and ischemic lesions revealed by MS have been shown for the first time.

Entities:  

Mesh:

Year:  2005        PMID: 15717628

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

1.  Chronotropic incompetence, echocardiographic abnormalities and exercise intolerance in renal transplant recipients.

Authors:  Maggie Kam Man Ma; Ming Lang Zuo; Desmond Yat Hin Yap; Maggie Ming Yee Mok; Lorraine Pui Yuen Kwan; Gary Chi Wang Chan; David Chung Wah Siu; Tak Mao Chan
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

2.  Effects of vagus nerve stimulation via cholinergic anti-inflammatory pathway activation on myocardial ischemia/reperfusion injury in canine.

Authors:  Rong Zhang; Najina Wugeti; Juan Sun; Huang Yan; Yujun Guo; Ling Zhang; Mei Ma; Xingui Guo; Changan Jiao; Wenli Xu; Tianqi Li; Haili Liu; Yitong Ma
Journal:  Int J Clin Exp Med       Date:  2014-09-15

Review 3.  Prognostic significance and therapeutic option of heart rate variability in chronic kidney disease.

Authors:  Jing Zhang; Ningning Wang
Journal:  Int Urol Nephrol       Date:  2013-03-29       Impact factor: 2.370

4.  Preserved autonomic heart rate modulation in chronic renal failure patients in response to hemodialysis and orthostatism.

Authors:  Claudia Lerma; Hortensia González; Hector Pérez-Grovas; Marco V José; Oscar Infante
Journal:  Clin Exp Nephrol       Date:  2014-05-30       Impact factor: 2.801

5.  The Association between Baseline Subjective Anxiety Rating and Changes in Cardiac Autonomic Nervous Activity in Response to Tryptophan Depletion in Healthy Volunteers.

Authors:  Chih Yin Hsiao; Hsin Chun Tsai; Mei Hung Chi; Kao Chin Chen; Po See Chen; I Hui Lee; Tzung Lieh Yeh; Yen Kuang Yang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

6.  The protective effect of isosteviol sodium on cardiac function and myocardial remodelling in transverse aortic constriction rat.

Authors:  Qingjin Ke; Fei Liu; Yuxin Tang; Jiedi Chen; Hui Hu; Xiaoou Sun; Wen Tan
Journal:  J Cell Mol Med       Date:  2020-12-17       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.